Physiogenex

Physiogenex is a leading preclinical research organization (CRO) specializing in a wide range of metabolic disorders. With a focus on conditions such as diabetes, insulin resistance, obesity, fatty liver diseases (NASH/NAFLD), dyslipidemia, atherosclerosis, and cardiovascular complications, Physiogenex is dedicated to advancing scientific understanding and therapeutic development.

Physiogenex offers a comprehensive suite of services including classical and proprietary diet-induced in vivo models, innovative in-house techniques such as RCT, and gold standard methods like glucose clamps with radiolabeled tracers. The organization also provides in vivo preclinical imaging services, ensuring detailed and precise data collection. Located at Prologue Biotech, 516 rue Pierre et Marie Curie, Labège, 31670, FR, Physiogenex is committed to delivering customized models and technologies tailored to meet specific research needs.

With unparalleled scientific expertise, Physiogenex supports R&D, preclinical development, post-marketing studies, and drug repositioning for both biopharmaceutical and nutraceutical companies. Physiogenex provides optimal and reliable solutions, empowering clients to make successful strategic decisions. We invite the management team at Physiogenex to create a customized and exclusive company showcase and product listing on our platform to further enhance their visibility and commercial success.